Cargando…

Day 30 SUV(max) predicts progression in patients with lymphoma achieving PR/SD after CAR T-cell therapy

About 70% of patients with large B-cell lymphoma (LBCL) who are treated with axicabtagene ciloleucel (axi-cel) and who achieve a partial response (PR) or stable disease (SD) on the day 30 (D30) positron emission tomography (PET)–computed tomography (CT) scan progress; however, the factors that are p...

Descripción completa

Detalles Bibliográficos
Autores principales:	Al Zaki, Ajlan, Feng, Lei, Watson, Grace, Ahmed, Sairah A., Mistry, Haleigh, Nastoupil, Loretta J., Hawkins, Misha, Nair, Ranjit, Iyer, Swaminathan P., Lee, Hun J., Steiner, Raphael E., Flowers, Christopher R., Shpall, Elizabeth J., Kebriaei, Partow, Neelapu, Sattva S., Westin, Jason R., Strati, Paolo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society of Hematology 2022
Materias:	Stimulus Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9092420/ https://www.ncbi.nlm.nih.gov/pubmed/35015825 http://dx.doi.org/10.1182/bloodadvances.2021006715

Ejemplares similares

Axicabtagene ciloleucel in relapsed or refractory large B-cell lymphoma patients in complete metabolic response
por: Jallouk, Andrew P., et al.
Publicado: (2022)

ASCT vs CART for patients with relapsed LBCL in PR: role of TMTV
por: Strati, Paolo, et al.
Publicado: (2023)

Prognostic impact of corticosteroids on efficacy of chimeric antigen receptor T-cell therapy in large B-cell lymphoma
por: Strati, Paolo, et al.
Publicado: (2021)

A phase 1 study of prophylactic anakinra to mitigate ICANS in patients with large B-cell lymphoma
por: Strati, Paolo, et al.
Publicado: (2023)

Hematopoietic recovery and immune reconstitution after axicabtagene ciloleucel in patients with large B-cell lymphoma
por: Strati, Paolo, et al.
Publicado: (2020)

P1092: A PHASE II INVESTIGATOR INITIATED STUDY OF ACALABRUTINIB, LENALIDOMIDE AND RITUXIMAB (AR2) IN PATIENTS WITH PREVIOUSLY UNTREATED HIGH TUMOR BURDEN FOLLICULAR LYMPHOMA
por: Strati, Paolo, et al.
Publicado: (2023)

Assessment of Radiation Doses Delivered to Organs at Risk Among Patients With Early-Stage Favorable Hodgkin Lymphoma Treated With Contemporary Radiation Therapy
por: Pinnix, Chelsea C., et al.
Publicado: (2020)

A polyamine-centric, blood-based metabolite panel predictive of poor response to CAR-T cell therapy in large B cell lymphoma
por: Fahrmann, Johannes F., et al.
Publicado: (2022)

Cardiovascular events in patients treated with chimeric antigen receptor T-cell therapy for aggressive B-cell lymphoma
por: Steiner, Raphael E., et al.
Publicado: (2021)

Partial omission of bleomycin for early‐stage Hodgkin lymphoma patients treated with combined modality therapy: Does incomplete ABVD lead to inferior outcomes?
por: Gunther, Jillian R., et al.
Publicado: (2020)

Radiation and CAR T-cell Therapy in Lymphoma: Future Frontiers and Potential Opportunities for Synergy
por: Fang, Penny Q., et al.
Publicado: (2021)

Impact of sickle cell trait on morbidity and mortality from SARS-CoV-2 infection
por: Merz, Lauren E., et al.
Publicado: (2021)

Risk assessment with low-pass whole-genome sequencing of cell-free DNA before CD19 CAR T-cell therapy for large B-cell lymphoma
por: Cherng, Hua-Jay J., et al.
Publicado: (2022)

Role of stem cell transplant in CD30(+) PTCL following frontline brentuximab vedotin plus CHP or CHOP in ECHELON-2
por: Savage, Kerry J., et al.
Publicado: (2022)

Invariant NKT cells dictate antitumor immunity elicited by a bispecific antibody cotargeting CD3 and BCMA
por: Casey, Mika, et al.
Publicado: (2022)

Coevolving JAK2(V617F+)relapsed AML and donor T cells with PD-1 blockade after stem cell transplantation: an index case
por: Penter, Livius, et al.
Publicado: (2021)

Convalescent plasma with a high level of virus-specific antibody effectively neutralizes SARS-CoV-2 variants of concern
por: Li, Maggie, et al.
Publicado: (2022)

A new role for the SRC family kinase HCK as a driver of SYK activation in MYD88 mutated lymphomas
por: Munshi, Manit, et al.
Publicado: (2022)

Regenerating islet-derived protein 3-α is a prognostic biomarker for gastrointestinal chronic graft-versus-host disease
por: DePriest, Brittany Paige, et al.
Publicado: (2022)

The CLL comorbidity index in a population-based cohort: a tool for clinical care and research
por: Rotbain, Emelie C., et al.
Publicado: (2022)

Gilteritinib-induced upregulation of S100A9 is mediated through BCL6 in acute myeloid leukemia
por: Zavorka Thomas, Megan E., et al.
Publicado: (2021)

Lasting shift in the gut microbiota in patients with acute myeloid leukemia
por: Rashidi, Armin, et al.
Publicado: (2022)

Physiologically based serum ferritin thresholds for iron deficiency in women of reproductive age who are blood donors
por: Addo, O. Yaw, et al.
Publicado: (2022)

HSCT using carrier donors for CD40L deficiency results in excellent immune function and higher CD40L expression in cTfh
por: Chandrakasan, Shanmuganathan, et al.
Publicado: (2022)

VpreB surrogate light chain expression in B-lineage ALL: a report from the Children’s Oncology Group
por: Winter, Stuart S., et al.
Publicado: (2022)

Long-term outcome of hyper-CVAD-R for Burkitt leukemia/lymphoma and high-grade B-cell lymphoma: focus on CNS relapse
por: Samra, Bachar, et al.
Publicado: (2021)

Allelic complexity of KMT2A partial tandem duplications in acute myeloid leukemia and myelodysplastic syndromes
por: Tsai, Harrison K., et al.
Publicado: (2022)

Associating drug sensitivity with differentiation status identifies effective combinations for acute myeloid leukemia
por: Kurtz, Stephen E., et al.
Publicado: (2022)

CD19-directed CAR T-cell therapy for treatment of primary CNS lymphoma
por: Siddiqi, Tanya, et al.
Publicado: (2021)

Outcomes of patients with CLL sequentially resistant to both BCL2 and BTK inhibition
por: Lew, Thomas E., et al.
Publicado: (2021)

Impact of histologic subtypes and treatment modality among patients with primary central nervous system lymphoma: a SEER database analysis
por: Chihara, Dai, et al.
Publicado: (2018)

CPX-351 induces remission in newly diagnosed pediatric secondary myeloid malignancies
por: Hu, Yixin, et al.
Publicado: (2022)

Clonal hematopoiesis is associated with increased risk of progression of asymptomatic Waldenström macroglobulinemia
por: Tahri, Sabrin, et al.
Publicado: (2022)

Outcomes of acute lymphoblastic leukemia with KMT2A (MLL) rearrangement: the MD Anderson experience
por: Richard-Carpentier, Guillaume, et al.
Publicado: (2021)

Clinical impact of NPM1-mutant molecular persistence after chemotherapy for acute myeloid leukemia
por: Tiong, Ing S., et al.
Publicado: (2021)

CBFB-MYH11 fusion transcripts distinguish acute myeloid leukemias with distinct molecular landscapes and outcomes
por: Huang, Benjamin J., et al.
Publicado: (2021)

Clinical care pathway for the evaluation of patients with suspected VITT after ChAdOx1 nCoV-19 vaccination
por: Lee, Agnes Y. Y., et al.
Publicado: (2022)

Real-world use of tisagenlecleucel in infant acute lymphoblastic leukemia
por: Moskop, Amy, et al.
Publicado: (2022)

Therapy of newly diagnosed follicular lymphoma
por: Westin, Jason R., et al.
Publicado: (2012)

Dissemination of extreme levels of extracellular vesicles: tissue factor activity in patients with severe COVID-19
por: Guervilly, Christophe, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ro5fe1b067b7gotvutovusciga